Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Sharma, Priyanka ^a   Kumar, Santosh ^a   Kundu, Gopal C ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; OSTEOPONTIN; PROTEIN C FOS; PROTEIN C JUN; RNA POLYMERASE II; TRANCRIPTION FACTOR AP1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR IIB; TRICHOSTATIN A; UNCLASSIFIED DRUG; URIDINE PHOSPHATE; HYDROXAMIC ACID; PRIMER DNA;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER INHIBITION; CARCINOMA CELL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE DELETION; GENE EXPRESSION; GENE REPRESSION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE C FOS; ONCOGENE C JUN; PROMOTER REGION; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION REGULATION; TUMOR VOLUME; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HELA CELL; NUCLEOTIDE SEQUENCE; RNA INTERFERENCE;

MUS;

BASE SEQUENCE; BLOTTING, WESTERN; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MUTAGENESIS, SITE-DIRECTED; OSTEOPONTIN; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION, GENETIC;

EID: 77954258432     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-178     Document Type: Article

References (50)

1. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000, 11:279-303. 10.1177/10454411000110030101, 11021631.
2. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, Kundu GC. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 2006, 6:819-830. 10.2174/156652406779010803, 17168734.
3. Senger DR, Asch BB, Smith BD, Perruzzi CA, Dvorak HF. A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature 1983, 302:714-715. 10.1038/302714a0, 6835406.
4. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994, 145:610-623. 1890312, 8080043.
5. Craig AM, Bowden GT, Chambers AF, Spearman MA, Greenberg AH, Wright JA, McLeod M, Denhardt DT. Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int J Cancer 1990, 46:133-137. 10.1002/ijc.2910460124, 2365496.
6. Giachelli CM, Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 2000, 19:615-622. 10.1016/S0945-053X(00)00108-6, 11102750.
7. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 2001, 1552:61-85.
8. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001, 107:1055-1061. 10.1172/JCI12980, 209291, 11342566.
9. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 2001, 6:419-429. 10.1023/A:1014734930781, 12013531.
10. Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001, 1:621-632. 10.2174/1566524013363339, 11899236.
11. Panda D, Kundu GC, Lee BI, Peri A, Fohl D, Chackalaparampil I, Mukherjee BB, Li XD, Mukherjee DC, Seides S, Rosenberg J, Stark K, Mukherjee AB. Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. Proc Natl Acad Sci USA 1997, 94:9308-9313. 10.1073/pnas.94.17.9308, 23171, 9256478.
12. Wai PY, Kuo PC. The role of OPN in tumor metastasis. J Surg Res 2004, 121:228-241. 10.1016/j.jss.2004.03.028, 15501463.
13. Rittling SR, Chen Y, Feng F, Wu Y. Tumor-derived osteopontin is soluble, not matrix associated. J Biol Chem 2002, 277:9175-9182. 10.1074/jbc.M109028200, 11741994.
14. Senger DR, Perruzzi CA, Papadopoulos A, Tenen DG. Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochim Biophys Acta 1989, 996:43-48.
15. Suzuki K, Zhu B, Rittling SR, Denhardt DT, Goldberg HA, McCulloch CA, Sodek J. Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J Bone Miner Res 2002, 17:1486-1497. 10.1359/jbmr.2002.17.8.1486, 12162503.
16. Felsenfeld G, Groudine M. Controlling the double helix. Nature 2003, 421:448-453. 10.1038/nature01411, 12540921.
17. Spotswood HT, Turner BM. An increasingly complex code. J Clin Invest 2002, 110:577-582. 151116, 12208855.
18. Jenuwein T, Allis CD. Translating the histone code. Science 2001, 293:1074-1080. 10.1126/science.1063127, 11498575.
19. Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2001, 15:2343-2360. 10.1101/gad.927301, 11562345.
20. Allfrey VG. Structural modifications of histones and their possible role in the regulation of ribonucleic acid synthesis. Proc Can Cancer Conf 1966, 6:313-335.
21. Johnson CA, Turner BM. Histone deacetylases: complex transducers of nuclear signals. Semin Cell Dev Biol 1999, 10:179-188. 10.1006/scdb.1999.0299, 10441071.
22. Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D. Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 2001, 11:162-166. 10.1016/S0959-437X(00)00174-X, 11250139.
23. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1:194-202. 10.1038/35106079, 11902574.
24. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001, 70:81-120. 10.1146/annurev.biochem.70.1.81, 11395403.
25. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001, 92:1300-1304.
26. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, Daigo Y, Russell P, Wilson A, Sowter HM, Delhanty JD, Ponder BA, Kouzarides T, Caldas C. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000, 24:300-303. 10.1038/73536, 10700188.
27. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-428. 10.1038/nrg962, 12042769.
28. Lehrmann H, Pritchard LL, Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 2002, 86:41-65. full_text, 12374280.
29. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 1998, 95:10860-10865. 10.1073/pnas.95.18.10860, 27986, 9724795.
30. Kawai H, Li H, Avraham S, Jiang S, Avraham HK. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer 2003, 107:353-358. 10.1002/ijc.11403, 14506733.
31. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990, 265:17174-17179.
32. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 2002, 99:11700-11705. 10.1073/pnas.182372299, 129332, 12189205.
33. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996, 93:5705-5708. 10.1073/pnas.93.12.5705, 39124, 8650156.
34. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001, 13:477-483. 10.1097/00001622-200111000-00010, 11673688.
35. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. Cancer Cell 2003, 4:13-18. 10.1016/S1535-6108(03)00165-X, 12892709.
36. Philip S, Kundu GC. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 2003, 278:14487-14497. 10.1074/jbc.M207309200, 12473670.
37. Liu YN, Kang BB, Chen JH. Transcriptional regulation of human osteopontin promoter by C/EBP and AML-1 in metastatic cancer cells. Oncogene 2004, 23:278-288. 10.1038/sj.onc.1207022, 14712233.
38. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 2008, 68:152-161. 10.1158/0008-5472.CAN-07-2126, 18172307.
39. Marks PA, Rifkind RA, Richon VM, Breslow R. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin Cancer Res 2001, 7:759-760.
40. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000, 97:10014-10019. 10.1073/pnas.180316197, 27656, 10954755.
41. Munster PN, Troso-Sandoval T, Rosen N, Rifkind RA, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001, 61:8492-8497.
42. Fass DM, Butler JE, Goodman RH. Deacetylase activity is required for cAMP activation of a subset of CREB target genes. J Biol Chem 2003, 278:43014-43019. 10.1074/jbc.M305905200, 12939274.
43. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, Osada H, Komatsu Y, Nishino N, Khochbin S, Horinouchi S, Yoshida M. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 2002, 24:6820-6831.
44. Gabrielli BG, Johnstone RW, Saunders NA. Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress. Curr Cancer Drug Targets 2002, 2:337-353. 10.2174/1568009023333818, 12470210.
45. Kouzarides. Acetylation: A regulatory modification to rival phosphorylation?. EMBO J 2000, 19:1176-1179. 10.1093/emboj/19.6.1176, 305658, 10716917.
46. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS. Modulation of p53, ErbB1, ErbB2 and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002, 94:504-513.
47. Sakata R, Minami S, Sowa Y, Yoshida M, Tamaki T. Trichostatin A activates the osteopontin gene promoter through AP1 site. Biochem Biophys Res Commun 2004, 315:959-963. 10.1016/j.bbrc.2004.01.152, 14985105.
48. Sakamoto S, Potla R, Larner AC. Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes. J Biol Chem 2004, 279:40362-40367. 10.1074/jbc.M406400200, 15194680.
49. Rascle A, Johnston JA, Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol 2003, 23:4162-4173. 10.1128/MCB.23.12.4162-4173.2003, 156147, 12773560.
50. Qiu L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parsons PG. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 1999, 80:1252-1258. 10.1038/sj.bjc.6690493, 2362353, 10376979.